|Bid||4.140 x 700|
|Ask||4.150 x 2000|
|Day's Range||3.866 - 4.380|
|52 Week Range||0.670 - 6.960|
|PE Ratio (TTM)||3.25|
|Earnings Date||Mar 13, 2017 - Mar 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
The company is spending more on interest than it's making in revenue. But can growing sales for Afrezza address fears about MannKind's debt?
The hottest stock among short sellers is Applied Optoelectronics Inc (NASDAQ: AAOI ), according to data compiled by FIS Astec Analytics. Applied Optoelectronics moves up to the hottest short stock from ...
NEW YORK, NY / ACCESSWIRE / October 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
WESTLAKE VILLAGE, Calif., Oct. 12, 2017-- MannKind Corporation announced the company’ s support for Hurricane Maria victims in Puerto Rico with a donation of Afrezza ® inhalation power. The donation will ...
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / MannKind and bluebird bio both dipped into red territory on Wednesday. Despite no negative news from bluebird, shares still sank nearly 5%. Shares of Mannkind, ...
Shares of MannKind Corp. tumbled 8.4% in premarket trade Wednesday, after the inhaled therapeutics products maker announced overnight an offering of common stock, as the company takes advantage of a tripling ...
WESTLAKE VILLAGE, Calif., Oct. 11, 2017-- MannKind Corporation and today announced that it entered into definitive agreements with certain institutional investors and other investors in connection with ...
In the past 3 weeks, MannKind has tripled to $6.75, bringing the year-to-date return on Nate Pile's fund to 34.82%. Here's what's behind MannKind's strong gains and what Nate is doing about it.
MannKind (MNKD:Nasdaq) By Maxim Group ($5.30, Oct. 6, 2017) In the wake of recent news that the Food and Drug Administration has approved the label revision for Afrezza (including a demonstration of the “speed” at which Afrezza delivers insulin and manages blood sugar), we see reduced risk in the MannKind story. The result is that our price target on MannKind climbs to $7, from $4.
Mylan The FDA approved the company’s generic version of a multiple-sclerosis treatment that’s been a big seller for Teva and for Momenta. GoPro Alphabet unit Google unveiled a clip-on camera that will be cheaper than some of GoPro’s wearable devices. MBIA After Hurricane Maria blasted Puerto Rico’s bonds, President Trump discouraged hopes for a federal bailout.
U.S. stock futures are trending cautiously higher this morning, as Wall Street waits for the release of September jobs data. Overall, about 17.2 million calls and 13.3 million puts changed hands, driven largely by a series of dividend capture plays amid corporate payouts. Taking a closer look at Thursday’s volume, MannKind Corporation (NASDAQ:MNKD) saw call options volume spike after it won a labeling battle with the Food and Drug Administration that should boost sales of its inhalable insulin product Afrezza.
MannKind Corp.'s stock rocketed Thursday on very heavy volume, putting it on track to post a third-straight 20+% gain, after the Food and Drug Administration updated prescribing information for the company's ...